Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden.

CEO

Dr. Tord Labuda M.Sc., Ph.D.

Employees

Country

Sweden

ISIN

SE0007413455

Listings

0 Comments

Share your thoughts

FAQ

What is Alzinova stock price today?▼

The current price of 78D.STU is €0.04 EUR — it has increased by +0% in the past 24 hours. Watch Alzinova stock price performance more closely on the chart.

What is Alzinova stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Alzinova stocks are traded under the ticker 78D.STU.

Is Alzinova stock price growing?▼

78D.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Alzinova has showed a -72.5% decrease.

When is the next Alzinova earnings date?▼

Alzinova is going to release the next earnings report on May 14, 2026.

How many employees does Alzinova have?▼

As of April 12, 2026, the company has 5 employees.

In which sector is Alzinova located?▼

Alzinova operates in the Health & Wellness sector.

When did Alzinova complete a stock split?▼

Alzinova has not had any recent stock splits.

Where is Alzinova headquartered?▼

Alzinova is headquartered in Mölndal, Sweden.